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Introduction
Gene-expression  profiling  allows  simultaneous,  semi-
quantitative  measurements  of  thousands  of  different 
mRNA species in a single experiment. It was considered 
logical to assume that different cancers will have distinct 
gene-expression patterns and that the expression of many 
genes will be associated with clinically relevant disease 
outcomes in particular cancer types. Consequently, it was 
assumed these associations might be exploited to develop 
a  new  generation  of  multi-gene  diagnostic  tests,  in 
particular prognostic and treatment response predictors.
It has quickly become apparent that cancers of different 
organs  have  very  different  gene-expression  patterns; 
indeed, this fact led to the development of a novel gene-
expression-based  molecular  diagnostic  test  to  assign  a 
histological origin to metastatic cancers that present as 
‘cancers  of  unknown  primary’  [1].  Gene-expression 
profiling results also prompted re-evaluation of disease 
classification for certain tumors, most prominently breast 
cancer. Breast cancer used to be considered as a single 
disease with variable histological appearance and variable 
expression of estrogen receptor (ER) and other molecular 
markers.  Gene-expression  profiling  studies  revealed 
surprisingly  large-scale  molecular  differences  between 
ER-positive and ER-negative cancers that suggested that 
these two different types of breast cancers are distinct 
diseases  [2-4].  A  new  molecular  classification  schema 
was proposed, but how many molecular classes there are 
and what method is best to assign these classes continues 
to be debated [5]. Currently, there is no standard, readily 
available,  gene-expression-based  test  to  determine  the 
molecular class of breast cancer in the clinic.
Molecular classification emerged through unsupervised 
analysis of gene-expression data. The goal of this analysis 
is  to  identify  disease  subsets  that  show  similar  gene-
expression  patterns  within  a  larger  cohort  of  cases. 
During this analysis, the molecular subsets are defined 
without  considering  clinical  outcome  information. 
Consequently, the emerging molecular subsets may or may 
not differ in prognosis or response to various therapies. A 
parallel  research  effort  has  focused  on  developing 
supervised outcome predictors. This approach relies on 
comparing  cases  with  known  outcome  (such  as 
recurrence versus no recurrence). The goal of the analysis 
is  to  identify  differentially  expressed  genes  between 
outcome groups and use these genes to develop a multi-
gene  outcome  predictor.  Evaluation  of  the  predictive 
accuracy of the supervised model requires independent 
validation  cases.  Investigators  who  developed  the  first 
generation  of  supervised  prognostic  and  treatment 
response  predictors  started  with  the  then  prevailing 
notion  that  breast  cancer  is  a  single  disease,  and  all 
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This  resulted  in  major  limitations  in  the  diagnostic 
products that emerged from this research [6,7].
The plethora of prognostic gene signatures for 
breast cancer
Unsupervised  molecular  classification  identified  three 
major and robust groups of breast cancers that differ in 
the  expression  of  several  hundred  to  a  few  thousand 
genes. These include basal-like breast cancers, which are 
negative for ER, progesterone receptor (PR) and human 
epidermal  growth  factor  receptor  2  (HER2);  low 
histological grade ER-positive breast cancers (also called 
luminal  A);  and  high  grade,  highly  proliferative  ER-
positive  cancers  (luminal  B).  Several  smaller  and  less 
stable  molecular  subsets  (such  as  normal-like,  HER-2-
positive and claudin-low) have also been proposed but 
are less consistently seen and are distinguished by sub-
stan  tially smaller molecular differences [4,5]. Importantly, 
among  the  various  molecular  subsets,  one  group,  the 
luminal  A  class  that  includes  low  grade  ER-positive 
cancers, stands out with a very favorable prognosis with 
or without adjuvant endocrine therapy. The other groups 
have worse but rather similar prognosis [4,8].
If  one  understands  these  close  associations  between 
clinical phenotype, molecular class and prognosis, it is no 
longer  surprising  that  comparing  gene-expression 
profiles of breast cancers that recurred (mostly the ER-
negative  and  the  high  grade,  ER-positive  cancers)  and 
those that did not (low grade, ER-positive cancers) in the 
absence of any systemic therapy (or after anti-estrogen 
therapy alone in the case of ER-positive cancers) yields a 
very large number of differentially expressed genes. The 
relative  position  of  individual  genes  in  a  rank-ordered 
gene list varies greatly, but the consistency of the gene list 
membership  is  fairly  high  across  various  datasets  [9]. 
Functional annotation indicates that the majority of these 
prognostic genes are proliferation-related genes and the 
remainder  are  mostly  ER-associated  and,  to  a  lesser 
extent,  immune-related  genes  [10-12].  Because  these 
genes function together in a coordinated manner in the 
regulation and execution of complex biological processes, 
such as cell proliferation, or originate from a particular 
cell type, such as immune cell infiltrate, many of these 
prognostic genes are also highly co-expressed with one 
another. It is therefore expected that a large number of 
nominally  different  prognostic  signatures  can  be 
constructed that all perform equally well.
For  example,  a  particular  gene  may  be  highly 
significantly  discriminating  in  two  datasets  but  it  is 
ranked 5th among the most discriminating genes in one 
dataset  (based  on  P-value  or  fold  difference)  but  only 
35th  in  another  dataset  (which  is  still  very  high 
considering  the  thousands  of  comparisons!).  In 
multivariate  prediction  model  building,  the  top  few 
informative features are usually combined and genes are 
added  incrementally  to  increase  the  predictive 
performance. However, because many of the genes are 
highly correlated with each other, adding genes lower on 
the list yields less and less improvement in the model as a 
result  of  lack  of  independence.  Therefore,  the  gene  in 
question will be included in a predictor developed from 
the  first  dataset  (because  it  is  ranked  as  5th)  and  will 
work well on validation in the second dataset; but if a 
new  predictor  were  to  be  developed  from  the  second 
dataset, this gene may not be included in the predictor 
(because it is ranked 35th). These three features of the 
breast cancer prognostic gene space – the large number 
of individually prognostic features, the unstable rankings, 
and the highly correlated expression of informative genes 
–  explain  why  it  is  easy  to  construct  many  different 
prognostic predictors that perform equally well even if 
they  rely  on  nominally  different  genes  in  the  model. 
However,  this  does  not  mean  that  all  published 
prognostic gene signatures are equally ready for clinical 
use.
Before adoption in the clinic, a molecular diagnostic 
assay has to be standardized, the reproducibility within 
and  between  laboratories  and  stability  of  results  over 
time have to be demonstrated, and its predictive accuracy 
has to be validated in the right clinical context, preferably 
in  multiple  independent  cohorts  of  patients.  Most 
importantly,  clinical  utility  implies  that  the  assay 
improves clinical decision making and complements or 
replaces older standard methods, which in turn leads to 
better  patient  outcomes.  Few  published  prognostic 
predictors have met these criteria [13,14].
Why signatures work less well than expected
The  predictive  performance  of  a  multivariate  model 
largely  depends  on  the  number  of  independent 
informative genes included in the model, the magnitude 
of differential expression of the informative genes and the 
complexity  of  the  background.  Different  clinical 
prediction problems show different degrees of difficulty. 
From  the  discussion  above  it  should  be  apparent  that 
prediction  of  ER  status,  histological  grade  of  breast 
cancer, or better or worse prognosis associated with these 
clinical  phenotypes  should  be  relatively  easy  when 
considering  all  breast  cancers  together,  and  that  such 
predictions  can  therefore  yield  predictors  with  good 
overall  accuracy.  Indeed,  prognostic  gene  signatures 
developed for breast cancer in general or for ER-positive 
cancers tend to have good performance characteristics 
[12,15-17].
However,  the  first-generation  prognostic  signatures 
share  some  limitations.  Because  these  were  invariably 
developed  by  analyzing  all  subtypes  of  breast  cancers 
Iwamoto and Pusztai Genome Medicine 2010, 2:81 
http://genomemedicine.com/content/2/11/81
Page 2 of 4together, they tend to assign high risk category to almost 
all  ER-negative  cancers  (which  are  almost  always  high 
grade),  even  though  a  substantial  majority  of  these 
cancers have good prognosis [18,19]. Similarly, the good- 
and poor-prognosis ER-positive cancers, as assigned by 
gene profiling, tend to correspond to the clinically low 
grade/low  proliferation  versus  high  grade/high 
proliferation  subsets,  respectively.  This  strong 
correlation  between  prognostic  risk  as  predicted  by 
gene signatures and routine clinical variables, such as 
histological  grade,  proliferation  rate  and  ER  status, 
limits the practical value of these tests. Efforts are under 
way to develop simple multivariate prognostic models 
that  use  routine  pathological  variables  (such  as  ER, 
histologic  grade  and  HER2  status),  and  these  could 
eventually rival the performance of the first-generation 
prognostic  gene  signa  tures  [20,21].  However, 
standardization of the patho  logical assessment of breast 
cancer  and  reducing  the  inter-observer  variability 
remains an important challenge.
Predicting  clinical  outcome,  such  as  prognosis  or 
response  to  chemotherapy,  within  clinically  and 
molecularly more homogeneous subsets (such as triple-
negative  breast  cancers  or  high  grade,  ER-positive 
cancers) would be highly desirable. Unfortunately, these 
prediction problems seem to be more difficult [22,23]. It 
seems that fewer genes are associated with outcome in 
homogeneous  disease  subsets  and  the  magnitude  of 
association is modest when currently available datasets 
are analyzed. This leads to predictors that are specific for 
a  particular  dataset  from  which  they  were  developed. 
These prediction models are fitted to the dataset and rely 
on features that have no or limited generalizability. This 
means  that  they  fail  to  validate  when  applied  to 
independent  data  or  may  demonstrate  only  nominally 
significant  predictive  value  (that  is,  they  may  predict 
outcome slightly better than chance). Also, the discrimi-
na  ting  value  may  not  be  substantial  enough  to  be 
clinically  useful  [24,25].  For  example,  if  the  good-
prognosis  group  has  a  recurrence  rate  of  30% 
compared with 50% in the poor-risk group, these may 
be significantly different but the risk of recurrence in 
the  good-risk  group  is  still  too  high  to  safely  forego 
adjuvant chemotherapy.
Can we improve prediction through new 
technology platforms and improved bioinformatics 
tools?
It seems that for certain clinical prediction problems, the 
currently  available  breast  cancer  gene-expression 
datasets may not contain enough information to be able 
to develop highly accurate predictors [22,23]. This may 
reflect limitations of the sample sizes for the subsets of 
interest  and,  as  more  data  become  available,  the 
empirically developed models may improve. However, it 
is  also  possible  that  major  advances  will  need  to  take 
place in our understanding of how the 10,000 to 12,000 
genes expressed in breast cancer interact before we can 
construct  more  accurate  prediction  models.  Current 
statistical  methods  cannot  readily  adjust  for  different 
levels of gene-expression change that may be required for 
a functional effect. The level of expression change that 
results in a functional change may be different from gene 
to gene: for some genes a 15 to 20% increase in mRNA 
expression  level  may  lead  to  functional  consequences, 
whereas for others a 100 to 150% change may be needed.
New bioinformatics approaches, such as examining the 
information content of the correlation matrix of gene-
expression values or applying network analysis tools to the 
data, may also reveal additional prognostic information 
that is not readily revealed by studying gene-expression 
levels  alone.  New  analytical  platforms,  such  as  next 
generation sequencing, will generate more comprehensive 
expression  data  than  the  current  array-based  methods 
and will also yield extensive nucleotide sequence infor-
ma  tion.  The  information  content  of  these  currently 
nascent datasets may be highly relevant to prognosis or 
treatment  response  of  cancers  and  certainly  warrants 
further exploration.
Conclusions
The  predictive  performance  of  multi-gene  signatures 
depends on the number and robustness of informative 
genes  that  are  associated  with  the  outcome  to  be 
predicted. Some clinically important prediction problems 
are easier to solve than others. For example, it is possible 
to  predict  the  prognosis  of  ER-positive  breast  cancers 
relatively accurately because prognosis is closely related 
to  the  proliferative  status  of  these  cancers  and 
proliferation affects the expression of several hundreds of 
genes  that  regulate  and  execute  cell  division.  Not 
surprisingly,  several  different  models  that  use  different 
genes  and  different  algorithms  can  be  built  with  each 
performing  similarly.  On  the  other  hand,  predicting 
response to individual drugs based on gene-expression 
signatures has proved substantially more difficult. Fewer 
genes are significantly associated with these outcomes, 
measured  on  current  analytical  platforms  (gene-
expression  arrays),  and  therefore  prediction  models 
invariably  contain  substantial  amounts  of  ‘noise’ 
(predictive features that are specific to the dataset, not 
the  actual  outcome)  and  have  poorer  predictive 
performance  on  independent  datasets.  Larger  datasets 
and  new  analytical  platforms  (such  as  next  generation 
sequencing) that broaden the portfolio of variables that 
can be used for model building are expected to lead to 
improved  predictors  for  these  currently  difficult 
classification problems.
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